The children in these groups were older at diagnosis (median 9.3 years in DUX4-IGH and 10.7 in ZNF384-rearranged vs 4.5 years in BCP-ALL) and exhibited similar clinical outcome as in previous studies [9, 14, 15, 41–43]. This evidence concerns the gene ZNF384 and acute lymphoblastic leukemia.